Drug manufacturers Xellia Pharmaceuticals and Chartwell Rx have notified 340B covered entities about possible refunds for overcharges.
Xellia Pharmaceuticals
Xellia notified 340B covered entities about refunds for overcharges on 16 NDCs for its antibiotics vancomycin, daptomycin, and colistimethate.
Xellia posted
…
Correction, Tuesday, May 25, 4:50 p.m. ET – Earlier today, we reported that the wholesale acquisition price for some of the generic PrEP products is now less than $30 per pill. The correct price is less than $30 per
United Therapeutics is holding off on requiring 340B covered entities to turn over their contract pharmacy claims data in order to get 340B pricing on drugs shipped to those pharmacies. The policy was supposed to take effect today. It will
…
Drug manufacturer Takeda’s designated specialty pharmacy and distributor for its leukemia drug Iclusig is making 340B covered entities declare on a form whether they will opt in or opt out of 340B pricing on purchases, as a condition for obtaining
…
Katheryne Richardson, a long time Apexus vice president who was instrumental in launching its 340B University educational program and Apexus Answers call center, is moving to Bristol-Myers Squibb (BMS) to become the drug manufacturer’s 340B program strategist.
Her move to
…
Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.
Between 3% and 5% of 340B drug discounts and Medicaid drug rebates are duplicates, adding up to at least $933 million and potentially as high as $1.6 billion in additional costs to the pharmaceutical industry in 2019, according to new
…
*Sign up for news summaries and alerts from 340B Report
